Gastroparesis Research Pipeline

According to NIH funding data, a moderate amount of public research funding has been directed toward gastroparesis, which suggests the condition has attracted meaningful scientific attention at a government level. However, the direction of that funding has been falling year on year, which may mean that research interest or government prioritisation is shifting away from this area over time. For patients, this pattern is worth noting, as sustained funding tends to support the development of new treatments and a better understanding of the condition.

Registry data shows trial activity at both early and late stages, meaning that research into gastroparesis has progressed beyond the purely experimental and that some treatments are being tested in more advanced settings. Early stage trials, such as Phase 1 and Phase 2 work, suggest researchers are still exploring new approaches, while later stage activity points to treatments that have already cleared initial safety hurdles. This combination of early and late stage activity is generally a sign of a pipeline that is moving forward, though it does not guarantee that any particular treatment will ultimately become available.

For Australian patients, the picture is less clear at a local level. No TGA approvals for gastroparesis treatments are currently recorded in the available data, and no PBS listing status has been recorded either, meaning there is no confirmed information about subsidised access through standard Australian channels. No patent activity has been recorded, which limits what can be said about commercial development interest in this space. Patients in Australia should speak with their treating doctor about what options may currently be accessible to them.

This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.